Company Encyclopedia
View More
name
Soleno Therapeutics
SLNO.US
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc.
1.902 T
SLNO.USMarket value -Rank by Market Cap -/-

Financial Score

14/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking82/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-20.66%E
    • Profit Margin-79.50%E
    • Gross Margin98.27%A
  • Growth ScoreC
    • Revenue YoY0.00%C
    • Net Profit YoY40.19%B
    • Total Assets YoY102.18%A
    • Net Assets YoY86.93%A
  • Cash ScoreD
    • Cash Flow Margin-125.78%D
    • OCF YoY0.00%C
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreA
    • Gearing Ratio17.52%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Will Vykat XR Approval and Board Shift Reshape Soleno Therapeutics' (SLNO) Investment Narrative?

    Soleno Therapeutics is experiencing a shift in its investment narrative following the FDA approval of Vykat XR, the only approved therapy for hyperphagia in Prader-Willi syndrome. The company is also undergoing board changes with Andrew Sinclair expected to assume the Audit Committee Chair role after the passing of William G. Harris. Analysts are optimistic about Vykat XR's potential, but risks include high valuation, unprofitability, and a new leadership team. Investors are encouraged to consider various perspectives on Soleno's long-term potential.

    Simplywall·
    US
    SLNO
    +5.07%
    Simplywall·
    US
    SLNO
    +5.07%

    Optimistic Outlook for Soleno Therapeutics: Potential Synergy of Vykat in Niche Market Segments

    Kate Dellorusso from LifeSci Capital maintains a Buy rating for Soleno Therapeutics with a $110 price target. The optimism is based on the potential synergy of Vykat in combination therapies, especially for patients with conditions like diabetes. Despite mixed trial results, there's hope for clearer insights by 2026. The focus on patient segmentation in Prader-Willi syndrome could benefit Soleno in niche markets.

    Tip Ranks·
    US
    SLNO
    +5.07%
    Tip Ranks·
    US
    SLNO
    +5.07%

    Soleno Therapeutics (NASDAQ:SLNO) Shares Gap Up - What's Next?

    Soleno Therapeutics (NASDAQ:SLNO) shares gapped up, opening at $53.33 from a previous close of $50.00, and last traded at $49.7560. Analysts have given the stock a consensus 'Buy' rating with a price target of $111.46. The company reported strong earnings, beating estimates with $0.47 EPS and $66.02 million in revenue. Institutional investors have significantly increased their holdings in the company. Soleno Therapeutics focuses on developing treatments for rare diseases, with its lead candidate in Phase III clinical trials for Prader-Willi Syndrome.

    Market Beat·
    US
    SLNO
    +5.07%
    Market Beat·
    US
    SLNO
    +5.07%

    CRNX, CYTK, MDGL, SLNO: Top Analyst Outlines Her 'Top Biotech Ideas for 2026'

    Top Piper Sandler analyst Yasmeen Rahimi shares her top biotech stock picks for 2026, including CRNX, CYTK, MDGL, and SLNO, citing strong drug rollout plans and potential approvals. She expects a constructive year for the biotech sector with ongoing launches and regulatory decisions. Rahimi highlights NAMS, PRAX, SVRA, and UNCY for potential 2026 approvals, supported by strong data.

    Tip Ranks·
    US
    CYTK
    +4.25%
    US
    SLNO
    +5.07%
    US
    MDGL
    +0.02%
    Tip Ranks·
    US
    CYTK
    +4.25%
    US
    SLNO
    +5.07%
    US
    MDGL
    +0.02%

    17:23 ET Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses

    Johnson Fistel, PLLP is investigating Soleno Therapeutics, Inc. for potential violations of federal securities laws. The investigation focuses on whether Soleno made false or misleading statements about VYKAT™ XR's commercial progress and safety. Following a critical report by Scorpion Capital, Soleno's stock price dropped nearly 40%. Shareholders who incurred losses are encouraged to join the investigation.

    prnewswire·
    US
    SLNO
    +5.07%
    prnewswire·
    US
    SLNO
    +5.07%
    © 2025 Longbridge｜Disclaimer